Literature DB >> 8538742

A role for glucagon-like peptide-1 in the central regulation of feeding.

M D Turton1, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert, J P Wilding, D M Smith, M A Ghatei, J Herbert, S R Bloom.   

Abstract

The sequence of glucagon-like peptide-1 (7-36) amide (GLP-1) is completely conserved in all mammalian species studied, implying that it plays a critical physiological role. We have shown that GLP-1 and its specific receptors are present in the hypothalamus. No physiological role for central GLP-1 has been established. We report here that intracerebroventricular (ICV) GLP-1 powerfully inhibits feeding in fasted rats. ICV injection of the specific GLP-1-receptor antagonist, exendin (9-39), blocked the inhibitory effect of GLP-1 on food intake. Exendin (9-39) alone had no influence on fast-induced feeding but more than doubled food intake in satiated rats, and augmented the feeding response to the appetite stimulant, neuropeptide Y. Induction of c-fos is a marker of neuronal activation. Following ICV GLP-1 injection, c-fos appeared exclusively in the paraventricular nucleus of the hypothalamus and central nucleus of the amygdala, and this was inhibited by prior administration of exendin (9-39). Both of these regions of the brain are of primary importance in the regulation of feeding. These findings suggest that central GLP-1 is a new physiological mediator of satiety.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8538742     DOI: 10.1038/379069a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  439 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Drug treatment of obesity: from past failures to future successes?

Authors:  P Collins; G Williams
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

4.  Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system.

Authors:  Carrie Yuen Yee Cheng; Jessica Yan Shuen Chu; Billy Kwok Chong Chow
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

5.  The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties.

Authors:  D M Irwin; M Satkunarajah; Y Wen; P L Brubaker; R A Pederson; M B Wheeler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 6.  Integrated circuits and molecular components for stress and feeding: implications for eating disorders.

Authors:  J A Hardaway; N A Crowley; C M Bulik; T L Kash
Journal:  Genes Brain Behav       Date:  2015-01       Impact factor: 3.449

7.  Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.

Authors:  Tao Ma; Xueliang Du; Joseph E Pick; Guangzhi Sui; Michael Brownlee; Eric Klann
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

8.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

Review 9.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

10.  Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

Authors:  Diana L Williams; Denis G Baskin; Michael W Schwartz
Journal:  Endocrinology       Date:  2008-12-12       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.